Engineered BMAP-27 nanoregulators synergize autophagy and metabolic reprogramming to combat atherosclerosis and hepatic steatosis.

Atherosclerosis (AS) remains the leading cause of cardiovascular disease mortality, often exacerbated by co-existing conditions like hepatic steatosis. Current therapeutic strategies for AS predominantly focus on isolated pathological links, such as lipid deposition or inflammation, neglecting the crucial interplay with systemic metabolic dysfunction, particularly liver health. This narrow focus limits their overall effectiveness in controlling the complex progression of AS. There's a critical need for integrated approaches that can simultaneously address plaque pathology and systemic metabolic derangements, leveraging mechanisms like autophagy and targeted drug delivery.